Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6364-6374

  Wang, Zhiqiang ^a   Da Silva, Thiago G ^a   Jin, Ke ^a   Han, Xiaoqing ^a   Ranganathan, Prathibha ^a   Zhu, Xiaoxia ^a   Sanchez Mejias, Avencia ^a   Bai, Feng ^a   Li, Bin ^a   Fei, Dennis Liang ^a   Weaver, Kelly ^a   Vasquez Del Carpio, Rodrigo ^a   Moscowitz, Anna E ^a   Koshenkov, Vadim P ^a   Sanchez, Lilly ^a   Sparling, Lynne ^a   Pei, Xin Hai ^a,b   Franceschi, Dido ^a,b   Ribeiro, Afonso ^a,b   Robbins, David J ^a,b   Livingstone, Alan S ^a,b   Capobianco, Anthony J ^a,b   more..

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; SECRETASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE GUIDED BIOPSY; MAJOR CLINICAL STUDY; MARKER GENE; MOUSE; NONHUMAN; NOTCH SIGNALING; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; DRUG SCREENING; ESOPHAGUS TUMOR; GENETICS; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CARCINOGENESIS; ESOPHAGEAL NEOPLASMS; HUMANS; MICE; NEOPLASTIC STEM CELLS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84909609672     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2051     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among White Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7.
3. Lassen A, Hallas J, de Muckadell OB. Esophagitis: incidence and risk of esophageal adenocarcinoma-a population-based cohort study.Am J Gastroenterol 2006;101:1193-9.
4. Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008;103:2694-9.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
6. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 2004;6:11-6.
7. Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda-Pedraza E, et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2007;102:497-506.
8. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003;27:999-1008.
9. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
10. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995;268:225-32.
11. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev 2011;11:338-51.
12. Fei DL, Sanchez-Mejias A, Wang Z, Flaveny C, Long J, Singh S, et al. Hedgehog signaling regulates bladder cancer growth and tumorigenicity. Cancer Res 2012;72:4449-58.
13. Singh S, Wang Z, Fei DL, Black KE, Goetz JA, Tokhunts R, et al. Hedgehog-producing cancer cells respond to and require autocrine hedgehog activity. Cancer Res 2011;71: 4454-63.
14. Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 2012; 107:1488-97.
15. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008;14:6456-68.
16. Kim SM, Park Y-Y, Park ES, Cho JY, Izzo JG, Zhang D, et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PloS One 2010;5:e15074.
17. Ardalan B, Spector SA, Livingstone AS, Franceschi D, Mezentsev D, Lima M, et al. Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer. Jpn J Clin Oncol 2007; 37:590-6.
18. Solomon N, Mezentsev D, Reis I, Lima M, Rios J, Avisar E, et al.Aphase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma. Jpn J Clin Oncol 2011;41:469-76.
19. Allan BJ, Pedroso F, Gennis ER, Livingstone AS, Montero A, Lally B, et al. Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas. Ann Surg Oncol 2013;20: 1660-7.
20. Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP. The Wnt/betacatenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010;9:212.
21. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 2012; 52:735-46.
22. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287-9.